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MODEL FARMAKOEKONOMI UNTUK VAKSIN DENGGI DI 
MALAYSIA 
 
 
ABSTRAK 
 
 
Lebih kurang dua bilion orang terdedah kepada jangkitan denggi di kawasan 
tropika dan subtropika, di mana kira-kira 50 hingga 100 juta jangkitan denggi 
berlaku setiap tahun, yang menyebabkan 20000 hingga 30000 kematian setiap 
tahun. Denggi ialah penyakit virus bawaan nyamuk yang disebarkan kepada 
manusia melalui gigitan nyamuk betina yang membawa virus. Kawalan wabak 
denggi sukar dicapai, terutamanya kerana kegagalan untuk mengawal habitat 
pembiakan nyamuk di persekitaran bandar. Vaksin denggi yang selamat, berkesan 
dan kos-efektif masih dalam ujian. Model yang menghubungkan dinamik penularan 
virus dari nyamuk kepada manusia adalah kunci kepada penilaian telus harga vaksin 
denggi. Dalam kajian ini, satu model dalaman bernama MOSSEIR dibangunkan 
dan digunakan untuk simulasi dinamik penularan denggi di Shah Alam dan 
Selangor. Kemudian, dinamik penularan denggi dikenal pasti dengan menerbitkan 
nombor pembiakan asas Ro. Analisis kepekaan untuk Ro menunjukkan bahawa 
kadar kematian semula jadi dan kadar gigitan nyamuk betina dewasa adalah 
parameter penting dalam penularan denggi. Strategi kawalan, iaitu penghapusan 
kawasan pembiakan nyamuk, semburan kabus nyamuk dan vaksinasi, dinilai 
melalui model MOSSEIR. Dari segi teori, hasil simulasi menunjukkan bahawa 
ketiga-tiga strategi kawalan ini dapat, secara ketaranya, mengurangkan penularan 
denggi. Sebenarnya, keberkesanan kaedah kawalan tradisional seperti penghapusan 
kawasan pembiakan nyamuk dan semburan kabus nyamuk adalah di bawah 
jangkaan kerana ketidakpatuhan. Oleh itu, penggunaan vaksin yang selamat, 
xx 
 
berkesan dan berpatutan harganya masih merupakan prospek terbaik untuk kawalan 
denggi. Suatu model farmakoekonomi dibangunkan dengan menghubungkan hasil 
model MOSSEIR dengan mekanisme harga vaksin untuk menilai ambang harga 
yang sangat kos-efektif untuk Malaysia. Ambang harga vaksin yang sangat kos-
efektif untuk pelbagai senario vaksinasi di Shah Alam, Selangor dan Malaysia 
ditunjukkan. Berpandukan hasil simulasi, bagi vaksin denggi yang selamat dan 
berkesan, ambang harga yang berpatutan dan lestari sebanyak USD5.00 setiap dos 
untuk Malaysia disokong.
xxi 
 
PHARMACOECONOMIC MODEL OF DENGUE VACCINE IN 
MALAYSIA  
 
 
ABSTRACT 
 
 
Around two billion people are vulnerable to dengue infections in tropical 
and subtropical regions, where about 50 to 100 million dengue infections occur each 
year, leading to 20000 to 30000 deaths annually. Dengue is a mosquito-borne viral 
disease that is transmitted to humans through the bites of female mosquitoes 
carrying the virus. Control of dengue epidemic has been elusive, mainly because of 
the failure to control mosquito breeding habitats in urban environments. Safe, 
efficacious and cost-effective dengue vaccine is still under testing. The model that 
links the virus transmission dynamics between mosquito and human is the key to a 
transparent valuation of dengue vaccine pricing. In this study, an in-house 
mathematical model named MOSSEIR is developed and used to simulate the 
dengue transmission dynamics in Shah Alam and Selangor. The dengue 
transmission dynamics are then examined by deriving the basic reproduction 
number Ro. Sensitivity analysis for Ro shows that the natural mortality and the biting 
rate of adult female mosquito are significant parameters in dengue transmission. 
Control strategies, namely elimination of mosquito breeding sites control, fogging 
and vaccination, are evaluated by means of the MOSSEIR model. Simulation 
results indicate that these three control strategies can significantly reduce dengue 
transmission, in theory. In reality, the effectiveness of traditional control methods 
such as elimination of mosquito breeding sites and fogging is below expectation 
due to non-compliance. Therefore, the adoption of a safe, effective and affordable 
vaccine remains the best prospect for controlling dengue. A pharmacoeconomic 
xxii 
 
model is developed by linking the MOSSEIR model results with the vaccine pricing 
mechanism to evaluate a highly cost-effective price threshold for Malaysia. A 
highly cost-effective vaccine price threshold for various vaccination scenarios in 
Shah Alam, Selangor and Malaysia are demonstrated. Based upon the simulation 
results, for a safe and effective dengue vaccine, an affordable and sustainable 
pricing threshold of USD5.00 per dose for Malaysia is advocated. 
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CHAPTER 1 
 
INTRODUCTION   
 
1.1 Introduction to Dengue  
Dengue is a mosquito-borne viral disease transmitted by Aedes aegypti mosquito 
and it is one of the most important arboviral disease affecting human. Dengue virus 
(DENV) is classified under Flaviviridae virus family and it includes four distinct 
serotypes, namely DENV-1, DENV-2, DENV-3 and DENV-4 (Back and 
Lundkvist, 2013). Dengue is endemic in more than 128 countries and 3.97 billion 
people living in areas are exposed to the risk of dengue transmission (Brady et al., 
2012). It is suggested that the number of global dengue incidence is close to 400 
million per year (Murray et al., 2013) and it is ranked second to Malaria amongst 
deadly mosquito-borne diseases (Khan et al., 2014). Dengue transmission occurs 
when an infected female mosquito bites an individual, following a virus incubation 
for 4−10 days. Infected human serves as a source of virus for uninfected mosquitoes 
and the virus is transmitted when mosquitoes feed on an infected individual. Aedes 
aegypti bites to obtain blood for laying eggs and breeds in artificial water containers 
such as tyres, tin cans and ceramic pots. Dengue fever (DF) is the most common 
clinical syndrome accompanied by high fever (40°C), severe headache, and muscle 
and joint pains (WHO, 2009). In less than 5% of dengue cases, the disease develops 
into a more severe clinical syndrome, known as dengue haemorrhagic fever (DHF). 
The DHF together with plasma leakage results in circulatory failure which causes 
life-threatening dengue shock syndrome (Luz et al., 2009). 
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1.2 Dengue in Malaysia 
The first dengue case was reported in year 1902 in Penang, Malaysia (Pang and 
Loh, 2016). The first epidemic outbreak occurred in year 1973, with a total number 
of 969 dengue cases and 54 dengue deaths. The dengue transmission continues to 
circulate in the population and there is an upward trend in the total number of 
dengue cases in Malaysia (Mia et al., 2013). For example, there is an increment of 
250% dengue infections in year 2014 (Pang and Loh, 2016). The total number of 
dengue cases in Malaysia in year 1995 is 6,543 and increased to 101,357 in year 
2016 as shown in Figure 1.1 (MOH, 2016a). Figure 1.2 shows the number of dengue 
cases by states in Malaysia year 2016. In year 2016, Selangor has the highest 
number of dengue cases, which is 51,652 or 50.96% of total number of dengue 
cases in Malaysia.  
 
All the four distinct dengue serotypes coexist in Malaysia and the prevalent dengue 
serotype changes from year to year as shown in Figure 1.3 (Mudin, 2015). From 
Figure 1.3, DENV-3 is predominant from year 1992 to 1995 and 2001 to 2002. 
From year 1996 to 2012, the prevalent dengue serotype changes between DENV-1, 
DENV-2 and DENV-3. DENV-1 is predominant between year 1996 to 1998 and 
2002 to 2006. DENV-2 is predominant between year 1998 to 2000 and 2006 to 
2009. The percentage of DENV-4 is found to be small as compared to other three 
serotypes. From year 2013 to 2015, DENV-1 and DENV-2 are more prevalent 
compared to the other two serotypes.  
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With the upward trend of dengue cases in Malaysia, efforts have been taken by the 
government to lower dengue transmission. It is estimated that the government of 
Malaysia has spent USD73.5 million on dengue vector control activities in year 
2010 (Packierisamy et al., 2015). However, limited success is achieved by current 
control methods (Ong, 2016). The dengue incidence would continue to increase if 
no effective control strategies are implemented (Pang and Loh, 2016). This urges 
the development of dengue vaccine, where vaccine is thought to be one of the most 
cost-effective public health interventions and as a long-term dengue control 
measure (Marimuthu and Ravinder, 2016). Following this, the world’s first dengue 
vaccine is developed by Sanofi Pasteur and several dengue vaccine candidates are 
undergoing clinical trial phases (Pang and Loh, 2017; Wichmann et al., 2017). 
Therefore, dengue vaccination could be a key approach for effective dengue 
outbreak control in Malaysia. 
 
 
Figure 1.1: Dengue cases in Malaysia from year 1995 to 2016. 
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Figure 1.2: Number of dengue cases by states in Malaysia year 2016. 
 
 
Figure 1.3: Circulation of dengue serotypes in Malaysia from year 1990 to 2015. 
 
1.3 Dengue Vaccine 
The world’s first dengue vaccine, Dengvaxia which is developed by Sanofi Pasteur, 
is now available and first licensed in Mexico on December 2015 for the use in 
individuals 9−45 years of age living in endemic areas (Vannice et al., 2016). To 
date, Dengvaxia has been approved in more than 10 countries (Lyon, 2016). 
13 183 994
2009 2326 2576 2773 2852 3050 3668
3777
6180
8663
10641
51652
0
10000
20000
30000
40000
50000
60000
N
u
m
b
er
 o
f 
C
as
es
States
0
10
20
30
40
50
60
70
80
90
100
1
9
9
0
1
9
9
1
1
9
9
2
1
9
9
3
1
9
9
4
1
9
9
5
1
9
9
6
1
9
9
7
1
9
9
8
1
9
9
9
2
0
0
0
2
0
0
1
2
0
0
2
2
0
0
3
2
0
0
4
2
0
0
5
2
0
0
6
2
0
0
7
2
0
0
8
2
0
0
9
2
0
1
0
2
0
1
1
2
0
1
2
2
0
1
3
2
0
1
4
2
0
1
5
P
er
ce
n
ta
g
e 
(%
)
Year
DENV-1 DENV-2 DENV-3 DENV-4
5 
 
Dengvaxia is a tetravalent, recombinant, live-attenuated vaccine which provides 
protection by neutralising antibodies that are claimed to be equally effective against 
all the four dengue serotypes (Wichmann et al., 2017). An equal protection against 
all four dengue serotypes is important to prevent antibody dependent enhancement 
(ADE) which results in a higher risk of severe dengue such as DHF or dengue shock 
syndrome (DSS) during a secondary infection (Guzman and Vazquez, 2010; Pang 
and Loh, 2017). The administration of Dengvaxia in seropositive individuals 
(individuals who has previous dengue infection with at least one serotype) would 
boost the recipients’ immunity to levels comparable to individuals who experienced 
two natural infections (infected by dengue twice). The next infection would behave 
as post-secondary infection with a much lower risk of severe disease (Figure 1.4). 
Conversely, vaccination in seronegative individuals (individuals who has no 
previous dengue infection) acts as a “primary-like” infection. The subsequent 
infection (first natural infection) behaves as a “secondary-like” infection with a 
higher risk of severe disease (Ferguson et al., 2016; Flasche et al., 2016).  
 
Aside from Sanofi Pasteur, many research laboratories are developing dengue 
vaccine, including Walter Reed Army Institute of Research (WRAIR), Fiocruz, 
GlaxoSmithKline (GSK), Merck, Takeda and National Institute of Allergy and 
Infectious Diseases (NIAID) (Schwartz et al., 2015). The current stages of clinical 
trials of other vaccine candidates with predicted earliest licensure are shown in 
Table 1.1 (Pang and Loh, 2017). From Table 1.1, Dengvaxia, TV003 or TV005 and 
TDV are live attenuated chimeric vaccines. A live attenuated virus vaccine which 
contains attenuated pathogenic microorganisms, is known to produce a robust, 
long-lasting and broad immune response (Briggs et al., 2014). There is a higher 
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chance of developing an efficacious tetravalent vaccine by using a live attenuated 
virus vaccine. Currently on trial, the vaccine TV003 or TV005 is given as single 
dose which induces tetravalent responses in 74%–92% (TV003) and 90% (TV005) 
of flavivirus seronegative adults (Whitehead, 2016). Phase III trial is scheduled to 
begin in the early of 2016 to evaluate the long-term efficacy of TV003 (Pang and 
Loh, 2017).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4: Illustration of the assumed mode of action of vaccine Dengvaxia 
(Flasche et al., 2016). 
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Table 1.1 Current stages of clinical trials of some dengue vaccine candidates. 
Vaccine Company Type Stage Earliest 
Licensure 
CYD-TDV 
(Dengvaxia) 
Sanofi Pasteur Live attenuated 
chimeric 
Completed 2015 
TV003/ 
TV005 
NIH/NIAID/ 
Butantan Institute 
Live attenuated 
chimeric 
Phase III 2018−2019 
TDV Inviragen/ Takeda Live attenuated 
chimeric 
Phase III 2017−2018 
TDEN GSK/WRAIR Purified 
inactivated 
whole virus 
Phase II 2018 
V180 Merck/ NIAID Subunit Phase I ⎯ 
D1ME100 U.S. Naval Medical 
Institute 
DNA Phase I ⎯ 
 
The vaccine TDV is another live attenuated chimeric vaccine which is undergoing 
phase III clinical trial. The results of phase II trial of TDV imply that it is 
immunogenic for all four dengue serotypes in all age groups after 1 or 2 doses, 
irrespective of pre-vaccination dengue serostatus (Sirivichayakul et al., 2016). 
Phase III clinical trial of TDV involves 20,000 healthy children to assess the 
efficacy of TDV in averting symptomatic dengue fever of any severity (Pang and 
Loh, 2017). Consisting of purified inactivated whole virus, the vaccine TDEN is 
considered safer compared to the live dengue vaccine. However, the development 
of TDEN is hindered by a low immunogenicity and hence requires the use of certain 
adjuvants to strengthen TDEN for long-term protection (Liu et al., 2016). The 
examination of safety and immunogenicity of TDEN is scheduled to begin in 
December 2016. In phase II trial, the effectiveness of a prime-boost strategy with 
TDEN and a live attenuated dengue vaccine is under evaluation (Schwartz et al., 
2015). The vaccine V180 is an E-based recombinant subunit vaccine, which has 
completed the evaluation of safety and immunogenicity in phase I trial (Liu et al., 
2016; Pang and Loh, 2017). Developed by U.S. Naval Medical Institute, D1ME100 
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is a monovalent plasmid DNA vaccine, which completed phase I study and the work 
to improve its immunogenicity is ongoing (Liu et al., 2016). 
 
On 31st October 2016, Malaysia had conditionally registered Dengvaxia and phase 
IV study of Dengvaxia in Malaysia is currently conducted to further examine the 
vaccine efficacy and safety. This is because the results of the two phase III clinical 
trials of Dengvaxia indicates a modest protection to seronegative individuals in Asia 
(56.5%) and Latin America (60.8%) (Pang and Loh, 2017). Further, the vaccine 
efficacy against DENV-2 is the lowest, i.e., 35% and 42.3% in Asia and Latin 
America, respectively. Since DENV-2 is prevalent in Malaysia, a more conclusive 
data on the vaccine effectiveness and duration of protection is needed. The phase 
IV study would address questions such as safety according to age and serostatus of 
vaccinated population, adverse events after vaccination and overall effects on 
dengue incidence and hospitalized dengue (Wichmann et al., 2017).    
 
1.4 Vaccine Pricing 
Before the introduction of a new vaccine, the decision makers should consider its 
safety, cost-effectiveness, affordability and sustainability (WHO, 2014a). 
Demographic, clinical, epidemiological, economic data and the use of modelling 
approaches to simulate disease transmission dynamics should be considered in cost-
effectiveness analyses (Tozan, 2015). Since the price of dengue vaccine is 
unknown, a transparent pharmacoeconomic model of dengue vaccine is needed to 
assess the vaccine price. Price transparency would assist decision makers to 
evaluate the affordability in introducing a new vaccine, provide knowledge on how 
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to obtain lower price by changing procurement practices and provide comparative 
price information between countries (WHO, 2017).  
 
1.5 Research Questions 
The research questions of this study are: 
i. What are the vaccination effects on dengue transmission in Malaysia? 
ii. What are the economic and disease burden of dengue before and after 
vaccination in Malaysia? 
iii. What is the highly cost-effective price threshold of dengue vaccine in 
Malaysia? 
 
1.6 Objectives of the Study 
The objectives of this study are as follows: 
i. To develop a pharmacoeconomic model based on the dengue virus 
transmission model;  
ii. To assess the effectiveness of vaccination and other dengue mitigation 
measures; 
iii. To compare the highly cost-effective price threshold for dengue vaccine in 
Malaysia with that in other papers. 
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1.7 Scope of the study 
A pharmacoeconomic model will be developed by coupling the dengue virus 
dynamic transmission model that links human SEIR framework with mosquito 
ecology model (Koh and Teh, 2011; Rodrigues et al., 2012) with the pricing 
mechanism demonstrated in Coudeville and Garnet (2012) and Shepard et al. 
(2012). The vaccination impacts on dengue transmission model, economic and 
disease burden of dengue will be determined by means of model simulations. A 
highly cost-effective price threshold for dengue vaccine in Malaysia will be 
proposed. 
 
1.8 Significance of the Study 
The pharmacoeconomic model can help in advocating a transparent mechanism to 
evaluate highly cost-effective price threshold for dengue vaccine in Malaysia, 
following WHO guidelines. The country’s overall immunization and health care 
system could be improved with the use of a safe, efficacious and affordable dengue 
vaccine. 
 
1.9 Organization of Thesis 
This thesis begins with Chapter 1 which introduce the dengue disease and discuss 
the dengue transmission in Malaysia. With the growing dengue epidemic and 
ineffective control by traditional methods, the need of dengue vaccination is 
discussed for effective dengue outbreak control. However, the price of dengue 
vaccine is still undetermined so there is a need to evaluate the price of vaccine by 
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using a pharmacoeconomic model. Then, the research questions, objectives, scope, 
significance and organization of this study are presented. 
 
A literature review on the epidemiological models is provided in Chapter 2. The 
basic human SIR and SEIR models are described and the need of using a vector-
host model to illustrate the spread of dengue in Malaysia is highlighted. Several 
methods to derive the basic reproduction number, a key concept in the study of 
epidemiology, are reviewed. This is followed by a discussion on the importance of 
sensitivity analysis and the methods in doing so for basic reproduction number. 
Then, a review on vaccination models is provided to identify the most suitable 
vaccination model in Malaysia. Methods to calculate the disease and economic 
burden of dengue before and after vaccination are presented. Lastly, 
pharmacoeconomic studies involving the evaluation of dengue vaccine price are 
reviewed to determine the most suitable approach in assessing the vaccine price for 
Malaysia. 
 
Next, three types of vector-host dengue transmission model, ASI-SIR, ASEI-SIR 
and ASEI-SEIR models are introduced in Chapter 3. A comparison of basic 
reproduction number for each of these models is performed to determine the most 
suitable model. Then, MOSSEIR, which is developed based on ASEI-SEIR model 
is discussed and used to illustrate dengue transmission dynamics in Malaysia. 
Model validation is carried out by comparing the simulation results to the results 
reported in Rodrigues et al. (2012). Bifurcation and sensitivity analysis of basic 
reproduction number are also performed. Finally, curve fitting analysis is 
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performed to estimate the parameter values that reflect the dengue transmission 
dynamics in Shah Alam and Selangor for the year 2010. These parameter values 
are critical to illustrate the vaccination effects and evaluate the vaccine pricing in 
later chapters. 
 
Several dengue control strategies such as breeding sites reduction, mosquito 
fogging and public education which have been implemented in Malaysia are 
described in Chapter 4. Since dengue vaccination would be a new approach to 
reduce dengue transmission in Malaysia, a vaccination model, known as 
MOSSEIR-Vaccine is introduced to illustrate the effects of vaccination. Then, the 
basic reproduction number of MOSSEIR-Vaccine is derived and stability analyses 
at disease-free and endemic equilibria are performed to determine the conditions 
for the equilibria to be stable. After that, numerical analysis of control strategies, 
including breeding sites reduction, mosquito fogging and vaccination in Shah Alam 
are performed and examined. These simulation results on vaccination effects will 
be used to assess and project the price of vaccine for Malaysia in Chapter 5. 
 
In Chapter 5, a pharmacoeconomic model which links the MOSSEIR-Vaccine 
model and vaccine pricing model is developed. Dengue vaccination in Selangor is 
chosen to demonstrate the pricing mechanism due to data availability. Both the 
disease and economic burden of dengue before and after vaccination are calculated. 
This information will be needed in cost-effectiveness analysis of dengue vaccine. 
The relationship between vaccine price and incremental cost-effectiveness ratio is 
also described. After that, a highly cost-effective price threshold for Malaysia is 
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estimated. A highly cost-effective vaccine price threshold for different vaccination 
scenarios in Shah Alam, Selangor and Malaysia are also compared and analyzed. 
 
Finally, several conclusions are drawn in Chapter 6 based on the results of this 
study. The limitations of this study and recommendations for future research are 
also discussed. 
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 CHAPTER 2 
 
LITERATURE REVIEW   
 
2.1 Epidemiological Models  
Epidemiology is the study of the distribution and determinant of health-related 
states or events in specified population, and the application of this study to control 
of health problems (Kramer et al., 2010). The purposes of epidemiology study are 
to explain the aetiology of a disease, to determine the risk and protective factors, to 
estimate the disease burden, to forecast disease trends and to examine the 
effectiveness of interventions. Epidemiology modelling helps to identify the 
process involved in epidemiology of an infectious disease, to determine the most 
significant parameter and to provide guidance on control strategies. The knowledge 
provided by epidemiological models also assist in analysing the control strategies 
for newly emerging and re-emerging pathogens. For example, during the outbreak 
of severe acute respiratory syndrome (SARS), mathematical modelling was used to 
analyse the infectious disease data and evaluate the effectiveness of control 
strategies (Wallinga and Teunis, 2004).  
 
In general, there are two types of models which can be used to study epidemiology 
modelling, i.e., stochastic and deterministic models. Stochastic model depends on 
chance variation in risks of exposure, disease and other factors (Kipruto et al., 
2013). This model considers human heterogeneities and provides more 
understanding on individual-level modelling. However, the model could be 
laborious to set up and could become mathematically complex (Hori et al., 2003). 
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Deterministic model divides individuals into different compartments and explains 
what happens in each compartment with some degree of details. Requiring less data 
and is easier to set up, the deterministic models have become popular as they are 
able to provide useful insights to disease progression and control strategy (Kipruto 
et al., 2013). Therefore, deterministic model will be used to study dengue 
transmission in Malaysia. In the following section, three types of deterministic 
models will be discussed, i.e. SIR model, SEIR model and vector-host transmission 
model. 
 
2.1.1 SIR Model  
An epidemic may be described as a sudden outbreak of a disease that infects a 
substantial portion of the population in a region before it disappears (Keeling and 
Rohani, 2008). Consistent with most infectious diseases including dengue, it is 
assumed appropriately that the pathogen causes illness for a period, followed by 
immunity, which can be considered as lifelong over the duration of the simulations. 
This scenario can be formulated mathematically in a model called SIR, which 
describes three different states or groups of individuals in the population in terms 
of a system of differential equations. In SIR model, the human population is 
categorized into three groups: (a) Sh, the number of individuals who are susceptible 
to the disease, (b) Ih, the number of infected individuals and (c) Rh, the number of 
infected individuals who is removed from the possibility of being infected again or 
of spreading infection. The total human population (Nh) is Nh = Sh + Ih + Rh. The 
initial SIR model is proposed by Kermack and McKendrick in year 1927 (Chowell 
and Brauer, 2009). 
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 In the simplest case, the population demography (births, deaths and migration) is 
ignored because it is assumed that the time scale of disease spread is sufficiently 
fast and not to be affected by human births and deaths. Other assumptions include 
homogeneous human population, no disease-induced deaths (which means constant 
total human population) and lifelong immunity. There are only two transitions, i.e., 
Sh → Ih and Ih → Rh. The transition from Sh to Ih involves the disease transmission 
while the transition from Ih to Rh involves the movement of infected individuals to 
recovered class once they have recovered from the infection. If a longer-term 
persistence and endemic dynamics need to be explored, then the population 
demography is important. In this case, the human birth rate and natural mortality 
rate need to be included in SIR model (Chowell and Brauer, 2009; Keeling and 
Rohani, 2008).  
 
2.1.2 SEIR Model 
One unrealistic feature of SIR model described in Section 2.1.1 is that the 
individuals become infectious immediately upon infection. This is because at the 
initial inoculation of a very small number of pathogen units (bacteria or virus), the 
virus abundance is too low for active transmission. These individuals are infected 
but not yet infectious and are referred to as exposed individuals, represented by Eh. 
In this latent period, the virus multiples inside the body of a susceptible individual 
until a certain level, at which the infected individual becomes infectious. The 
addition of a latent period may act to introduce a slight time delay into the system 
(Keeling and Rohani, 2008). Therefore, the epidemic growth after the introduction 
of latent period in SEIR model may be slower due to the transition of susceptible 
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human population to exposed class before they can contribute to the transmission 
process.   
 
2.1.3 Vector-host Transmission Model 
The initial SIR model by Kermack and McKendrick has a great influence in the 
development of mathematical epidemiology models (Rodrigues, 2016). The SIR 
model is a beginning point to understand how the disease spreads. Refinement is 
possible in enriching the model and in adding more details in the model 
formulation. The choice of appropriate compartments of the model depends on the 
properties of the disease, data availability and the purposes of the study (Verelst et 
al., 2016). Dengue fever is a vector-borne disease which is transmitted via blood-
sucking arthropods known as vectors (Keeling and Rohani, 2008). It cannot be 
passed between primary hosts (person to person) but through an intermediate insect 
host or vector. The interactions between coupled mosquito-human population 
dynamics and dengue transmission play an important role in the development of 
dengue fever (Liao et al., 2015). Mathematical models which include both the 
mosquito and human population dynamics would enhance the understanding on the 
spread of this mosquito-borne disease. The mosquito entomological parameters 
such as the biting rate, virus incubation rate in mosquito and mosquito population 
dynamics are some of the key factors in dengue transmission. There is a need to 
understand the effects of changes in these parameters that would help in the 
planning of effective control strategies (Manore et al., 2014). For such purposes, a 
vector-host transmission model which includes both mosquito and human 
population is developed. 
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A vector-host transmission model described by Bailey (1975) provides the basis for 
a dengue transmission model that includes both the mosquito (SI model) and human 
populations (SIR model). Many models have been derived from this basic dengue 
model, depending on the assumptions of the model, the dengue epidemiology 
and/or transmission routes (Andraud et al., 2012). For example, the SI-SIR model 
may be extended to SEI-SEIR model to include both extrinsic incubation period 
(EIP) in mosquito and intrinsic incubation period (IIP) in human population. The 
EIP in mosquito is important because it is about the same duration as the mosquito 
lifespan and because the mosquito might die before it becomes infectious (Manore 
et al., 2014). The inclusion of exposed human compartment would reflect the reality 
that the infected human has to survive the IIP before he or she becomes infectious. 
Garba et al. (2008), Lashari and Zaman (2011) and Manore et al. (2014) use SEI-
SEIR model to illustrate the dengue transmission and perform mathematical 
analysis. 
 
The ASI-SIR or ASEI-SEIR model includes the aquatic mosquito population in the 
vector-host transmission model (Chen and Hsieh, 2012; Liao et al., 2015; Rodrigues 
et al., 2013). This would assist in the analysis of effects of aquatic mosquito 
entomological parameters such as the oviposition rate, maturation rate from larvae 
to adult and natural mortality of larvae in dengue transmission (Esteva and Yang, 
2015). The effects of vector control such as mosquito breeding sites control, 
application of larvicides and mosquito fogging can also be evaluated by using ASI-
SIR or ASEI-SEIR model (Barmak et al., 2014; Burattini et al., 2008; Rodrigues et 
al., 2013). This can be done by adding a control variable in mosquito compartments 
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(Rodrigues et al., 2013) or increasing the mosquitoes’ mortality rate (Burattini et 
al., 2008).  
 
Since the impacts of vector control can be demonstrated by using a vector-host 
transmission model, the most efficient control strategy could be identified from the 
model. For example, Amaku et al. (2014) suggests that the control of adult 
mosquitoes is the most effective control measure by performing sensitivity analysis. 
Therefore, an understanding on the life cycle of adult mosquitoes and the seasonal 
cycle of disease transmission would assist in a successful vector control. A two-
treatment cycle of mosquito fogging is based on the life cycle of adult mosquito and 
the EIP of mosquito (Lam, 1993). It is recommended that mosquito fogging be 
applied at the peak biting time especially during rainy season (Pang and Loh, 2016). 
Oki et al. (2011) suggests that the seasonality and the level of transmission intensity 
should be considered during mosquito fogging. Burattini et al. (2008) opines that a 
discrete application of fogging would be more feasible from the practical point of 
view and the impact of consistent fogging (four weekly fogging applications) is 
more durable when seasonality is considered in the dengue model. 
 
Moreover, the mosquito compartment can be extended to incorporate different 
dengue serotypes to assist in the analysis of a severe form of the dengue disease 
such as dengue haemorrhagic fever (DHF) and dengue shock syndrome (DSS). 
Such analysis would require at least two different dengue serotypes in the mosquito 
compartment (Kooi et al., 2014; Morales et al., 2017). There are also papers that 
consider four dengue serotypes to illustrate the immunological interactions between 
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the four dengue serotypes such as cross-protection and cross enhancement, which 
are the features of dengue transmission (Coudeville and Garnett, 2012; Hladish et 
al., 2016; Reich et al., 2013). For the human population, it can be extended to 
include heterogeneities in age. This can be done by dividing the human population 
into several age groups. Since dengue disease spreads differently in different age 
groups and the data from WHO shows that the majority of dengue patients are 
children (Aldila et al., 2013; Vicente et al., 2017), several papers consider human 
age groups in developing dengue model (Aldila et al., 2013; Cochran and Xu, 2014; 
Mello and Castilho, 2014).  
 
In general, both simple and complex models have been developed to explore dengue 
transmission (Ellis et al., 2011). One of the limitations of deterministic model is the 
assumption of homogeneous population, where each individual has the same 
amount of contacts. The spread of disease depends on the age groups, contact 
pattern and geographic location (Chao et al., 2013; Valle et al., 2013). These factors 
could be incorporated in a stochastic model but the model might become complex. 
A more complex model tends to be more realistic if the parameters are known but 
the behavior of a complex model might be difficult to investigate analytically (Ellis 
et al., 2011). After considering the availability of dengue data and the complexity 
of a model, a deterministic model consisting of the mosquito and human population 
will be used to demonstrate the dengue transmission dynamics in Malaysia. This 
model will be discussed in Chapter 3. The mosquito population is needed to provide 
deeper insight into the underlying mechanisms for the spread of dengue disease and 
suggest effective control strategies. The human age groups and multi-serotypes of 
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dengue are not considered because they are beyond the scope of this study and 
because of the limitation of data. 
 
2.2 Basic Reproduction Number 
An understanding on the potential spread of dengue disease and significant 
parameters influencing dengue transmission that could aid dengue control strategies 
can be derived from the dengue transmission model. This can be done by using 
basic reproduction number, Ro which is a key concept in the study of epidemiology 
and within-host pathogen dynamics. Developed for the study of vector-borne 
diseases, infectious diseases and in-host population dynamics, Ro is an indicator of 
transmissibility in a completely susceptible population. In general, Ro is the number 
of secondary cases produced by a single infected individual during his or her entire 
infectious period in a completely susceptible population (Chen et al., 2007; 
Heffernan et al., 2005). From this definition, when Ro < 1, each infected individual 
produces less than one new infected individual, indicating the disease cannot invade 
the population. If Ro > 1, the cases increase and epidemic may occur. In an endemic 
infection, Ro can be used to determine the most effective control measure in 
reducing Ro below one. The magnitude of Ro is used to estimate the potential risk 
of infectious disease such as SARS, foot and mouth disease, dengue, malaria and 
Ebola. Table 2.1 shows examples of Ro for some infectious diseases. 
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Table 2.1: Basic reproduction number, Ro of some infectious diseases. 
Diseases Ro References 
Measles 12-18 Fine (1993) 
Smallpox 5-7 Fine (1993) 
Rubella 6-7 Fine (1993) 
Malaria 5-100 Fine (1993) 
SARS 3.5 Gumel et al. (2004) 
H1N1 1.33 White et al. (2013) 
Ebola 1.5-2.5 Althaus (2014) 
Zika 2.06 Gao et al. (2016) 
 
There are several methods to derive Ro, such as the survival function, final size 
equation, intrinsic growth rate, average age at infection, the Jacobian method and 
the next generation method (NGM) (Heffernan et al., 2005). The final size equation, 
intrinsic growth rate and average age at infection are methods to estimate Ro from 
incidence data. The final size equation is applicable to closed populations only in 
which the infection leads either to immunity or death. In this case, the number of 
susceptible human population can only decrease and the final fraction of susceptible 
human is used to estimate Ro. The intrinsic growth rate is the rate at which the 
infected human population grows and the Ro can be estimated based on this rate. 
However, this method depends on the accuracy of incidence data and the estimation 
of Ro is highly model dependent. Average at infection is a method based on the 
endemic equilibrium and Ro can be estimated as l/A, where l is the mean lifetime 
and A is the mean age of acquiring the disease. 
 
The survival function, the Jacobian method and the NGM method are methods to 
derive Ro in terms of the parameters of some deterministic model. The Jacobian is 
used to derive a parameter that reflects the stability of the disease-free equilibrium. 
The parameter obtained may or may not reflect the biologically meaning value of 
Ro. For a more complex model with more infected compartments, it is difficult to 
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apply Jacobian method to derive Ro (Driessche, 2017). The Jacobian method is 
sufficient to predict whether the disease will persist or be eliminated. The survival 
function is used to handle situations in which infectivity depends on time. This 
method can be extended to describe models in which a series of states are involved 
in the production of newly infected individuals. However, this method becomes 
cumbersome when the infection cycles involve three or more states (Heffernan et 
al., 2005). In this situation, the NGM method will be more suitable in deriving Ro. 
The NGM method can be used to derive Ro when more than one class of infective 
is involved. In this method, the infection process is viewed as the generations of 
infected individuals (Diekmann et al., 2010). Subsequent generations growing in 
size indicates an epidemic and the growth factor per generation implies the potential 
for growth. This growth factor is given by the largest eigenvalue of the next-
generation matrix and is the mathematical characterization of Ro. The NGM method 
has been applied by a majority of papers on epidemiological modelling 
(Abboubakar et al., 2016; Aldila et al., 2013; Liao et al., 2015; Manore et al., 2014; 
Mishra et al., 2018; Morales et al., 2017; Rodrigues et al., 2013; Yang, 2014).  
 
Deriving Ro for a disease system could be a complex problem due to the 
involvement of several species, different epidemiological reactions at different life-
history stages and multiple transmission routes. The NGM method can be used to 
characterize Ro even in systems with such complexity (Hartemink et al., 2008). The 
Ro is one of the most important concepts in epidemiology modelling and NGM 
method provides a convenient way to perform such calculations (Hurford et al., 
2010). Hence, in this study, the NGM method will be used to derive Ro for dengue 
model to identify significant parameters in dengue transmission. 
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2.3 Sensitivity Analysis 
To control dengue transmission and to reduce dengue mortality, it is necessary to 
understand the relative importance of different factors responsible for dengue 
transmission and prevalence. Sensitivity analysis (SA) studies the variation of 
outputs of a model caused by variations in the inputs. It is usually performed as a 
series of tests where a different sets of input parameters is used to observe the 
change in dynamical behavior of the system. It helps to determine which parameters 
are the key drivers of a model’s results, to interpret the reasonable range of system 
outcomes and to identify the robustness of a modelling study’s qualitative 
conclusions (Wu et al., 2013). A highly sensitive parameter should be carefully 
estimated as a small variation in that parameter will result in a large change to 
outputs, while an insensitive parameter does not require as much effort to estimate 
as a small variation in that parameter will not produce a large change to results. 
Since the Ro represents the nature of disease transmission, sensitivity analysis (SA) 
is performed for Ro to determine the impact of model parameters on dengue 
transmission.  
 
There are several methods to perform SA which have been discussed by Hamby 
(1994), Wu et al. (2013) and Pianosi et al. (2016). In our study, SA using partial 
differentiation technique—the most fundamental technique of SA—is chosen 
because it is computationally efficient (Hamby, 1994) and has been applied by 
several studies (Burattini et al., 2008; Chitnis et al., 2008; Manore et al., 2014; Nie 
and Xue, 2017; Samsuzzoha et al., 2013; Toro et al., 2017). The results of SA in 
some studies suggest that the mosquito biting rate or/and mosquito mortality rate 
are major factors influencing Ro (Abboubakar et al., 2016; Burattini et al., 2008; 
